These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26833165)

  • 21. Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.
    Mendes RE; Paukner S; Doyle TB; Gelone SP; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of linezolid-resistant CoNS isolates in Japan.
    Takaya A; Kimura A; Sato Y; Ishiwada N; Watanabe M; Matsui M; Shibayama K; Yamamoto T
    J Antimicrob Chemother; 2015 Mar; 70(3):658-63. PubMed ID: 25381168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus.
    Tsakris A; Pillai SK; Gold HS; Thauvin-Eliopoulos C; Venkataraman L; Wennersten C; Moellering RC; Eliopoulos GM
    J Antimicrob Chemother; 2007 Sep; 60(3):649-51. PubMed ID: 17623697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.
    Mendes RE; Deshpande L; Streit JM; Sader HS; Castanheira M; Hogan PA; Flamm RK
    J Antimicrob Chemother; 2018 Jul; 73(7):1880-1887. PubMed ID: 29659858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.
    Jones RN; Moet GJ; Sader HS; Mendes RE; Castanheira M
    J Antimicrob Chemother; 2009 Apr; 63(4):716-20. PubMed ID: 19218276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linezolid surveillance results for the United States: LEADER surveillance program 2011.
    Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1077-81. PubMed ID: 23254424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
    Chen H; Wu W; Ni M; Liu Y; Zhang J; Xia F; He W; Wang Q; Wang Z; Cao B; Wang H
    Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
    Jones RN; Sader HS; Flamm RK
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):304-7. PubMed ID: 23357293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.
    Meka VG; Gold HS; Cooke A; Venkataraman L; Eliopoulos GM; Moellering RC; Jenkins SG
    J Antimicrob Chemother; 2004 Oct; 54(4):818-20. PubMed ID: 15347637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of linezolid- and methicillin-resistant coagulase-negative staphylococci in a tertiary hospital in China.
    Liu C; Yu J; Chen C; Li X; Ye Y; Dong Y; Ying X; Li H; Wang W
    BMC Infect Dis; 2024 May; 24(1):486. PubMed ID: 38730362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterisation of clinical meticillin-resistant Staphylococcus epidermidis demonstrating high levels of linezolid resistance (>256 μg/ml) resulting from transmissible and mutational mechanisms.
    Gabriel EM; Fitzgibbon S; Clair J; Coffey A; O'Mahony JM
    J Infect Chemother; 2015 Jul; 21(7):547-9. PubMed ID: 25913534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-Year Summary of
    Pfaller MA; Mendes RE; Streit JM; Hogan PA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linezolid Resistance in Methicillin-Resistant
    Yoo IY; Kang OK; Shim HJ; Huh HJ; Lee NY
    Ann Lab Med; 2020 Jan; 40(1):57-62. PubMed ID: 31432640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-infection by two linezolid-resistant coagulase-negative staphylococci with two different resistance determinants.
    Mazzariol A; Kocsis E; Bragagnolo L; Pellizzer G; Rassu M; Cornaglia G
    Scand J Infect Dis; 2012 Dec; 44(12):978-81. PubMed ID: 22830638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
    Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of the classical G2576U mutation in linezolid resistant Staphylococcus aureus along with isolation of linezolid resistant Enterococcus faecium from a patient on short-term linezolid therapy: first report from India.
    Rai S; Niranjan DK; Kaur T; Singh NP; Hada V; Kaur IR
    Indian J Med Microbiol; 2015; 33(1):21-4. PubMed ID: 25559997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
    Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.